Fate Therapeutics iPSC Effector Cells for Immunotherapy Patent EP4168538A1
Summary
The European Patent Office published patent application EP4168538A1 for Fate Therapeutics, Inc., covering methods of combining iPSC-derived effector cell types for immunotherapy use. The patent includes claims related to cell therapy compositions, cytokine combinations, and therapeutic applications for cancer treatment. The patent designation covers 31 European member states.
What changed
The EPO published patent application EP4168538A1, a granted patent for Fate Therapeutics, Inc. covering compositions and methods for combining induced pluripotent stem cell (iPSC)-derived effector cell types for immunotherapy applications. The patent includes broad claims across multiple International Patent Classification codes spanning pharmaceutical compositions (A61K), therapeutic preparations (A61P), peptides and proteins (C07K), and cell culture methods (C12N).
For competitors in the cell therapy and immunotherapy space, this patent establishes intellectual property barriers around iPSC-derived effector cell combinations. Companies developing similar cell therapy products for oncology applications may need to evaluate design-around options or pursue licensing discussions with Fate Therapeutics for the European market.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMBINING IPSC-DERIVED EFFECTOR CELL TYPES FOR IMMUNOTHERAPY USE
Publication EP4168538A1 Kind: A1 Apr 08, 2026
Applicants
Fate Therapeutics, Inc.
Inventors
VALAMEHR, Bahram, GOODRIDGE, Jode, BJORDAHL, Ryan
IPC Classifications
A61K 40/11 20250101AFI20260227BHEP A61K 40/15 20250101ALI20260227BHEP A61K 40/30 20250101ALI20260227BHEP A61K 40/31 20250101ALI20260227BHEP A61K 40/35 20250101ALI20260227BHEP A61K 40/42 20250101ALI20260227BHEP A61K 40/50 20250101ALI20260227BHEP A61K 45/06 20060101ALI20260227BHEP A61P 35/00 20060101ALI20260227BHEP C07K 14/54 20060101ALI20260227BHEP C07K 14/725 20060101ALI20260227BHEP C07K 14/735 20060101ALI20260227BHEP C07K 14/715 20060101ALI20260227BHEP C07K 16/28 20060101ALI20260227BHEP C12N 5/0783 20100101ALI20260227BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.